You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Version: 2 ID: GL END 9-10 aoû 2022
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
S. Das, L. Durocher-Allen, C. Hawkins, M. MacDonald, J. Perry, A. Sahgal, and the Adult Gliomas Expert Panel

Guideline Objective:

The objectives of this guideline are to provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumours in adults. Our recommendations are based on the 2021 guideline on “Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.”

Patient Population:

The target population is adults with gliomas who have received maximum safe surgical resection.

Intended Guideline Users:

The guideline is intended for oncologists (medical, radiation, neuro-oncology) and neurologists who provide care to people with glioma.

 

pdf download Full Report (PDF) (311.9 Ko)

Guideline-Based Clinical Tools

Critical Changes in Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Webinar Recording: Critical Changes in Therapy for Diffuse Astrocytic and Oligodendroglial Tumours in Adults.